Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease: A Matched-case Control Pilot Study

Jung H. Suh, Émilie Degagné, Elizabeth E. Gleghorn, Mala Setty, Alexis Rodriguez, K. T. Park, Sofia G. Verstraete, Melvin B. Heyman, Ashish S. Patel, Melissa Irek, Ginny L. Gildengorin, Neil Hubbard, Alexander D Borowsky, Julie D. Saba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Goal The aim of this study was to investigate gene expression levels of proteins involved in sphingosine-1-phosphate (S1P) metabolism and signaling in a pediatric inflammatory bowel disease (IBD) patient population. Background IBD is a debilitating disease affecting 0.4% of the US population. The incidence of IBD in childhood is rising. Identifying effective targeted therapies that can be used safely in young patients and developing tools for selecting specific candidates for targeted therapies are important goals. Clinical IBD trials now underway target S1PR1, a receptor for the pro-inflammatory sphingolipid S1P. However, circulating and tissue sphingolipid levels and S1P-related gene expression have not been characterized in pediatric IBD. Methods Pediatric IBD patients and controls were recruited in a four-site study. Patients received a clinical score using PUCAI or PCDAI evaluation. Colon biopsies were collected during endoscopy. Gene expression was measured by qRT-PCR. Plasma and gut tissue sphingolipids were measured by LC-MS/MS. Results Genes of S1P synthesis (SPHK1, SPHK2), degradation (SGPL1), and signaling (S1PR1, S1PR2, and S1PR4) were significantly upregulated in colon biopsies of IBD patients with moderate/severe symptoms compared with controls or patients in remission. Tissue ceramide, dihydroceramide, and ceramide-1-phosphate (C1P) levels were significantly elevated in IBD patients compared with controls. Conclusions A signature of elevated S1P-related gene expression in colon tissues of pediatric IBD patients correlates with active disease and normalizes in remission. Biopsied gut tissue from symptomatic IBD patients contains high levels of pro-apoptotic and pro-inflammatory sphingolipids. A combined analysis of gut tissue sphingolipid profiles with this S1P-related gene signature may be useful for monitoring response to conventional therapy.

Original languageEnglish (US)
Pages (from-to)1321-1334
Number of pages14
JournalInflammatory Bowel Diseases
Volume24
Issue number6
DOIs
StatePublished - May 18 2018

Fingerprint

Inflammatory Bowel Diseases
Case-Control Studies
Pediatrics
Sphingolipids
Genes
Gene Expression
Colon
sphingosine 1-phosphate
Biopsy
Ceramides
Population
Endoscopy
Therapeutics
Polymerase Chain Reaction
Incidence

Keywords

  • gene expression
  • inflammatory bowel disease
  • pediatric
  • sphingolipids
  • sphingosine-1-phosphate

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease : A Matched-case Control Pilot Study. / Suh, Jung H.; Degagné, Émilie; Gleghorn, Elizabeth E.; Setty, Mala; Rodriguez, Alexis; Park, K. T.; Verstraete, Sofia G.; Heyman, Melvin B.; Patel, Ashish S.; Irek, Melissa; Gildengorin, Ginny L.; Hubbard, Neil; Borowsky, Alexander D; Saba, Julie D.

In: Inflammatory Bowel Diseases, Vol. 24, No. 6, 18.05.2018, p. 1321-1334.

Research output: Contribution to journalArticle

Suh, JH, Degagné, É, Gleghorn, EE, Setty, M, Rodriguez, A, Park, KT, Verstraete, SG, Heyman, MB, Patel, AS, Irek, M, Gildengorin, GL, Hubbard, N, Borowsky, AD & Saba, JD 2018, 'Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease: A Matched-case Control Pilot Study', Inflammatory Bowel Diseases, vol. 24, no. 6, pp. 1321-1334. https://doi.org/10.1093/ibd/izy007
Suh, Jung H. ; Degagné, Émilie ; Gleghorn, Elizabeth E. ; Setty, Mala ; Rodriguez, Alexis ; Park, K. T. ; Verstraete, Sofia G. ; Heyman, Melvin B. ; Patel, Ashish S. ; Irek, Melissa ; Gildengorin, Ginny L. ; Hubbard, Neil ; Borowsky, Alexander D ; Saba, Julie D. / Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease : A Matched-case Control Pilot Study. In: Inflammatory Bowel Diseases. 2018 ; Vol. 24, No. 6. pp. 1321-1334.
@article{b7495809cf384844b750509aec206966,
title = "Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease: A Matched-case Control Pilot Study",
abstract = "Goal The aim of this study was to investigate gene expression levels of proteins involved in sphingosine-1-phosphate (S1P) metabolism and signaling in a pediatric inflammatory bowel disease (IBD) patient population. Background IBD is a debilitating disease affecting 0.4{\%} of the US population. The incidence of IBD in childhood is rising. Identifying effective targeted therapies that can be used safely in young patients and developing tools for selecting specific candidates for targeted therapies are important goals. Clinical IBD trials now underway target S1PR1, a receptor for the pro-inflammatory sphingolipid S1P. However, circulating and tissue sphingolipid levels and S1P-related gene expression have not been characterized in pediatric IBD. Methods Pediatric IBD patients and controls were recruited in a four-site study. Patients received a clinical score using PUCAI or PCDAI evaluation. Colon biopsies were collected during endoscopy. Gene expression was measured by qRT-PCR. Plasma and gut tissue sphingolipids were measured by LC-MS/MS. Results Genes of S1P synthesis (SPHK1, SPHK2), degradation (SGPL1), and signaling (S1PR1, S1PR2, and S1PR4) were significantly upregulated in colon biopsies of IBD patients with moderate/severe symptoms compared with controls or patients in remission. Tissue ceramide, dihydroceramide, and ceramide-1-phosphate (C1P) levels were significantly elevated in IBD patients compared with controls. Conclusions A signature of elevated S1P-related gene expression in colon tissues of pediatric IBD patients correlates with active disease and normalizes in remission. Biopsied gut tissue from symptomatic IBD patients contains high levels of pro-apoptotic and pro-inflammatory sphingolipids. A combined analysis of gut tissue sphingolipid profiles with this S1P-related gene signature may be useful for monitoring response to conventional therapy.",
keywords = "gene expression, inflammatory bowel disease, pediatric, sphingolipids, sphingosine-1-phosphate",
author = "Suh, {Jung H.} and {\'E}milie Degagn{\'e} and Gleghorn, {Elizabeth E.} and Mala Setty and Alexis Rodriguez and Park, {K. T.} and Verstraete, {Sofia G.} and Heyman, {Melvin B.} and Patel, {Ashish S.} and Melissa Irek and Gildengorin, {Ginny L.} and Neil Hubbard and Borowsky, {Alexander D} and Saba, {Julie D.}",
year = "2018",
month = "5",
day = "18",
doi = "10.1093/ibd/izy007",
language = "English (US)",
volume = "24",
pages = "1321--1334",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Sphingosine-1-Phosphate Signaling and Metabolism Gene Signature in Pediatric Inflammatory Bowel Disease

T2 - A Matched-case Control Pilot Study

AU - Suh, Jung H.

AU - Degagné, Émilie

AU - Gleghorn, Elizabeth E.

AU - Setty, Mala

AU - Rodriguez, Alexis

AU - Park, K. T.

AU - Verstraete, Sofia G.

AU - Heyman, Melvin B.

AU - Patel, Ashish S.

AU - Irek, Melissa

AU - Gildengorin, Ginny L.

AU - Hubbard, Neil

AU - Borowsky, Alexander D

AU - Saba, Julie D.

PY - 2018/5/18

Y1 - 2018/5/18

N2 - Goal The aim of this study was to investigate gene expression levels of proteins involved in sphingosine-1-phosphate (S1P) metabolism and signaling in a pediatric inflammatory bowel disease (IBD) patient population. Background IBD is a debilitating disease affecting 0.4% of the US population. The incidence of IBD in childhood is rising. Identifying effective targeted therapies that can be used safely in young patients and developing tools for selecting specific candidates for targeted therapies are important goals. Clinical IBD trials now underway target S1PR1, a receptor for the pro-inflammatory sphingolipid S1P. However, circulating and tissue sphingolipid levels and S1P-related gene expression have not been characterized in pediatric IBD. Methods Pediatric IBD patients and controls were recruited in a four-site study. Patients received a clinical score using PUCAI or PCDAI evaluation. Colon biopsies were collected during endoscopy. Gene expression was measured by qRT-PCR. Plasma and gut tissue sphingolipids were measured by LC-MS/MS. Results Genes of S1P synthesis (SPHK1, SPHK2), degradation (SGPL1), and signaling (S1PR1, S1PR2, and S1PR4) were significantly upregulated in colon biopsies of IBD patients with moderate/severe symptoms compared with controls or patients in remission. Tissue ceramide, dihydroceramide, and ceramide-1-phosphate (C1P) levels were significantly elevated in IBD patients compared with controls. Conclusions A signature of elevated S1P-related gene expression in colon tissues of pediatric IBD patients correlates with active disease and normalizes in remission. Biopsied gut tissue from symptomatic IBD patients contains high levels of pro-apoptotic and pro-inflammatory sphingolipids. A combined analysis of gut tissue sphingolipid profiles with this S1P-related gene signature may be useful for monitoring response to conventional therapy.

AB - Goal The aim of this study was to investigate gene expression levels of proteins involved in sphingosine-1-phosphate (S1P) metabolism and signaling in a pediatric inflammatory bowel disease (IBD) patient population. Background IBD is a debilitating disease affecting 0.4% of the US population. The incidence of IBD in childhood is rising. Identifying effective targeted therapies that can be used safely in young patients and developing tools for selecting specific candidates for targeted therapies are important goals. Clinical IBD trials now underway target S1PR1, a receptor for the pro-inflammatory sphingolipid S1P. However, circulating and tissue sphingolipid levels and S1P-related gene expression have not been characterized in pediatric IBD. Methods Pediatric IBD patients and controls were recruited in a four-site study. Patients received a clinical score using PUCAI or PCDAI evaluation. Colon biopsies were collected during endoscopy. Gene expression was measured by qRT-PCR. Plasma and gut tissue sphingolipids were measured by LC-MS/MS. Results Genes of S1P synthesis (SPHK1, SPHK2), degradation (SGPL1), and signaling (S1PR1, S1PR2, and S1PR4) were significantly upregulated in colon biopsies of IBD patients with moderate/severe symptoms compared with controls or patients in remission. Tissue ceramide, dihydroceramide, and ceramide-1-phosphate (C1P) levels were significantly elevated in IBD patients compared with controls. Conclusions A signature of elevated S1P-related gene expression in colon tissues of pediatric IBD patients correlates with active disease and normalizes in remission. Biopsied gut tissue from symptomatic IBD patients contains high levels of pro-apoptotic and pro-inflammatory sphingolipids. A combined analysis of gut tissue sphingolipid profiles with this S1P-related gene signature may be useful for monitoring response to conventional therapy.

KW - gene expression

KW - inflammatory bowel disease

KW - pediatric

KW - sphingolipids

KW - sphingosine-1-phosphate

UR - http://www.scopus.com/inward/record.url?scp=85047510641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047510641&partnerID=8YFLogxK

U2 - 10.1093/ibd/izy007

DO - 10.1093/ibd/izy007

M3 - Article

C2 - 29788359

AN - SCOPUS:85047510641

VL - 24

SP - 1321

EP - 1334

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 6

ER -